SavedAdd your journal

Journals / European Journal of Biology / 2025 / Volume: 84 Issue: 2

Therapeutic Peptides Targeting VEGF/VEGFR: Advances in Anti Angiogenic Therapy and the Role of Bioinformatics in Drug Design

Mohammad Mahagna(İSTANBUL AYDIN ÜNİVERSİTESİ)0009-0006-1268-0420
Berrin Erdağ(İSTANBUL AYDIN ÜNİVERSİTESİ)0000-0003-2241-1540
Pages
—
Publication Date
2025-12-18
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We also discuss previous studies that successfully used bioinformatics techniques to design and develop effective anti-angiogenic peptides.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Angiogenesis is a critical process in the formation of new blood vessels in both normal and pathological tissues.
📊
Key Findings & Data:In cancer, angiogenesis is important to provide oxygen and nutrients to tumour sites due to oxygen deficiency during hypoxia.
💡
Conclusion & Impact:We also discuss previous studies that successfully used bioinformatics techniques to design and develop effective anti-angiogenic peptides.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Angiogenesis · Anti-VEGF therapy · Peptide therapeutics

Abstract

Angiogenesis is a critical process in the formation of new blood vessels in both normal and pathological tissues. In cancer, angiogenesis is important to provide oxygen and nutrients to tumour sites due to oxygen deficiency during hypoxia. Vascular endothelial growth factor (VEGF) is a key regulator that activates various signalling pathways that are critical for angiogenesis by binding to the VEGF receptor (VEGFR). Targeting the VEGF/VEGFR signalling pathway, its receptor, or ligand can inhibit signalling and cause an anti-angiogenic effect. Various approaches have been developed to target the VEGF/VEGFR signalling pathway, including the most widely used monoclonal antibodies and tyrosine kinase inhibitors. Monoclonal antibodies show high target specificity, but due to their large size, they also cause high immunogenicity. Tyrosine kinase inhibitors are effective against intracellular targets but have limited capacity to target specific sites. Therapeutic peptides offer a promising alternative because of their small size, improved target selectivity, and chemical modification potential. The use of bioinformatics tools in therapeutic peptide development is time-efficient and provides a better understanding of peptide structure and activity. Bioinformatics tools help in designing therapeutic peptides, including structural and functional analysis, interaction analysis, structural prediction, and modification method testing. In this context, several anti-angiogenic peptides have been designed and developed with the help of bioinformatics tools. Here, we review the importance of the VEGF/VEGFR complex as a target for the development of anti-angiogenic drugs. We also discuss previous studies that successfully used bioinformatics techniques to design and develop effective anti-angiogenic peptides.

🔖

Cite This Article

Mahagna, M., Erdağ, B. (2025). Therapeutic Peptides Targeting VEGF/VEGFR: Advances in Anti Angiogenic Therapy and the Role of Bioinformatics in Drug Design. European Journal of Biology, Volume: 84 Issue: 2. https://doi.org/10.26650/EurJBiol.2025.1681311

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (77)

  1. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: Beyond discovery and development. Cell. 2019;176(6):1248–1264. doi:10.1016/j.cell.2019.01.021 google scholar
  2. Shaw P, Dwivedi SKD, Bhattacharya R, Mukherjee P, Rao G. VEGF signaling: Role in angiogenesis and beyond. Biochim Biophys Acta Rev Cancer. 2024;1879(2):189079. doi:10.1016/j.bbcan.2024.189079 google scholar
  3. Ahmad A, Nawaz MI. Molecular mechanism of VEGF and its role in pathological angiogenesis (69). J Cell Biochem. 2022;123(12):1938–1965. doi:10.1002/jcb.30344 google scholar
  4. Park SA, Jeong MS, Ha KT, Jang SB. Structure and function of vascular endothelial growth factor and its receptor system. BMB Rep. 2018;51(2):73–78. doi:10.5483/BMBRep.2018.51.2.233 google scholar
  5. Yang Y, Cao Y. The impact of VEGF on cancer metastasis and systemic disease. Semin Cancer Biol. 2022;86:251–261. doi:10.1016/j.semcancer.2022.03.011 google scholar
  6. Lee HJ, Hong YJ, Kim M. Angiogenesis in chronic inflammatory skin disorders. Int J Mol Sci. 2021;22(21):12035. doi:10.3390/ijms222112035 google scholar
  7. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116(10):2610–2621. doi:10.1172/JCI24612 google scholar
  8. Di Stasi R, De Rosa L, D’Andrea LD. Structure-based design of peptides targeting VEGF/VEGFRs. Pharmaceuticals. 2023;16(6). doi:10.3390/ph16060851 google scholar
  9. Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1). doi:10.1038/s41392-023-01460-1 google scholar
  10. Anand U, Bandyopadhyay A, Jha NK, Pérez de la Lastra JM, Dey A. Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate. BioFactors. 2022;49(2):251–269. doi:10.1002/biof.1913 google scholar
  11. Erak M, Bellmann-Sickert K, Els-Heindl S, Beck-Sickinger AG. Peptide chemistry toolbox – Transforming natural peptides into peptide therapeutics. Bioorg Med Chem. 2018;26(10):2759–2765. doi:10.1016/j.bmc.2018.01.012 google scholar
  12. Zhong F, Xing J, Li X, et al. Artificial intelligence in drug design. Sci China Life Sci. 2018;61(10):1191–1204. doi:10.1007/s11427-018-9342-2 google scholar
  13. Shaker B, Ahmad S, Lee J, Jung C, Na D. In silico methods and tools for drug discovery. Comput Biol Med. 2021;137:104851. doi:10.1016/j.compbiomed.2021.104851 google scholar
  14. Chang Y, Hawkins BA, Du JJ, Groundwater PW, Hibbs DE, Lai F. A guide to in silico drug design (68). Pharmaceutics. 2022;15(1):49. doi:10.3390/pharmaceutics15010049 google scholar
  15. Pérez-Gutiérrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol. 2023;24(11):816–834. doi:10.1038/s41580-023-00631-w google scholar
  16. Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular endothelial growth factor (VEGF) and its role in non-endothelial cells: Autocrine signalling by VEGF. Published online 2013. Accessed February 17, 2025. https://www.ncbi.nlm.nih.gov/books/NBK6482/ google scholar
  17. Lungu CN, Mehedinti MC. Molecular motifs in vascular morphogenesis: Vascular endothelial growth factor A (VEGFA) as the leading promoter of angiogenesis. Int J Mol Sci. 2023;24(15). doi:10.3390/ijms241512169 google scholar
  18. Peach CJ, Mignone VW, Arruda MA, et al. Molecular pharmacology of VEGF-A isoforms: Binding and signalling at VEGFR2. Int J Mol Sci. 2018;19(4). doi:10.3390/ijms19041264 google scholar
  19. Mabeta P, Steenkamp V. The VEGF/VEGFR axis revisited: Implications for cancer therapy. Int J Mol Sci. 2022;23(24). doi:10.3390/ijms232415585 google scholar
  20. Stevens M, Oltean S. Modulation of receptor tyrosine kinase activity through alternative splicing of ligands and receptors in the VEGF-A/VEGFR axis. Cells. 2019;8(4):288. doi:10.3390/cells8040288 google scholar
  21. Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res. 2023;29(1):30–39. doi:10.1158/1078-0432.CCR-22-1366 google scholar
  22. Shaik F, Cuthbert GA, Homer-Vanniasinkam S, Muench SP, Ponnambalam S, Harrison MA. Structural basis for vascular endothelial growth factor receptor activation and implications for disease therapy. Biomolecules. 2020;10(12):1–25. doi:10.3390/biom10121673 google scholar
  23. Cho HD, Moon KD, Park KH, Lee YS, Seo KI. Effects of auriculasin on vascular endothelial growth factor (VEGF)-induced angiogenesis via regulation of VEGF receptor 2 signaling pathways in vitro and in vivo. Food Chem Toxicol. 2018;121:612–621. doi:10.1016/j.fct.2018.09.025 google scholar
  24. Cho HD, Lee KW, Won YS, Kim JH, Seo KI. Cultivated Orostachys japonicus extract inhibits VEGF-induced angiogenesis via regulation of VEGFR2 signaling pathway in vitro and in vivo. J Ethnopharmacol. 2020;256:112664. doi:10.1016/j.jep.2020.112664 google scholar
  25. Geindreau M, Ghiringhelli F, Bruchard M. Vascular endothelial growth factor, a key modulator of the anti-tumor immune response. Int J Mol Sci. 2021;22(9):4871. doi:10.3390/ijms22094871 google scholar
  26. Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, Lorenc T. Exosomes in angiogenesis and anti-angiogenic therapy in cancers. Int J Mol Sci. 2020;21(16):5840. doi:10.3390/ijms21165840 google scholar
  27. Lopes-Coelho F, Martins F, Pereira SA, Serpa J. Anti-angiogenic therapy: Current challenges and future perspectives. Int J Mol Sci. 2021;22(7):3765. doi:10.3390/ijms22073765 google scholar
  28. Yan X, Zhao Z, Tang H. Current status and future of anti-angiogenic drugs in lung cancer. Clin Exp Med. 2023;23(6):2009–2023. doi:10.1007/s10238-023-01039-8 google scholar
  29. Wang L, Liu WQ, Broussy S, Han B, Fang H. Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis. Front Pharmacol. 2024;14. doi:10.3389/fphar.2023.1307860 google scholar
  30. Kong DH, Kim M, Jang J, Na HJ, Lee S. A review of anti-angiogenic targets for monoclonal antibody cancer therapy. Int J Mol Sci. 2017;18(8):1786. doi:10.3390/ijms18081786 google scholar
  31. Han K, Peyret T, Marchand M, et al. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol. 2016;78(2):341–351. doi:10.1007/s00280-016-3079-6 google scholar
  32. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2005;7(4):335–345. doi:10.1007/s10456-004-8272-2 google scholar
  33. Pataky RE, Beca J, Tran D, et al. Real-world cost-effectiveness of bevacizumab with first-line combination chemotherapy in patients with metastatic colorectal cancer. MDM Policy Pract. 2021;6(1). doi:10.1177/23814683211021060 google scholar
  34. Sinha SD, Biswas G, Bheemareddy BR, et al. A real-world study of safety, immunogenicity and efficacy of bevacizumab in patients with solid malignancies. Cancer Inform. 2023;22. doi:10.1177/11769351231177277 google scholar
  35. Kohlberger M, Gadermaier G. SELEX: Critical factors and optimization strategies for successful aptamer selection. Biotechnol Appl Biochem. 2021;69(5):1771–1792. doi:10.1002/bab.2244 google scholar
  36. Nimjee SM, White RR, Becker RC, Sullenger BA. Aptamers as therapeutics. Annu Rev Pharmacol Toxicol. 2017;57(1):61–79. doi:10.1146/annurev-pharmtox-010716-104558 google scholar
  37. Maier KE, Levy M. From selection hits to clinical leads: Progress in aptamer discovery. Mol Ther Methods Clin Dev. 2016;3:16014. doi:10.1038/mtm.2016.14 google scholar
  38. Jaakkonen A, Volkmann G, Iwaï H. An off-the-shelf approach for the production of Fc fusion proteins by protein trans-splicing. Int J Mol Sci. 2020;21(11):4011. doi:10.3390/ijms21114011 google scholar
  39. Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2017;9(1):15–32. doi:10.1007/s13238-017-0408-4 google scholar
  40. Liu Y, Li Y, Wang Y, et al. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. J Hematol Oncol. 2022;15(1). doi:10.1186/s13045-022-01310-7 google scholar
  41. Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y. Targeting tyrosine kinases in ovarian cancer. Biomedicines. 2022;10(9):2113. doi:10.3390/biomedicines10092113 google scholar
  42. Ramadan WS, Zaher DM, Altaie AM, Talaat IM, Elmoselhi A. Antiangiogenesis resistance mechanisms in lung and breast cancers. Int J Mol Sci. 2020;21(2):565. doi:10.3390/ijms21020565 google scholar
  43. Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to anti-angiogenic therapy in cancer. Int J Mol Sci. 2018;19(4):1232. doi:10.3390/ijms19041232 google scholar
  44. Wang L, Wang N, Zhang W, et al. Therapeutic peptides: Current applications and future directions. Signal Transduct Target Ther. 2022;7(1). doi:10.1038/s41392-022-00904-4 google scholar
  45. Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2023 FDA TIDES harvest. Pharmaceuticals. 2024;17(2):243. doi:10.3390/ph17020243 google scholar
  46. Baghban R, Ghasemali S, Farajnia S, et al. Design and in silico evaluation of a novel cyclic disulfide-rich anti-VEGF peptide. Int J Pept Res Ther. 2021;27(4):2245–2256. doi:10.1007/s10989-021-10250-8 google scholar
  47. Barman P, Joshi S, Sharma S, et al. Strategic approaches to improvise peptide drugs. Int J Pept Res Ther. 2023;29(4). doi:10.1007/s10989-023-10524-3 google scholar
  48. Fetse J, Kandel S, Mamani UF, Cheng K. Recent advances in therapeutic peptides. Trends Pharmacol Sci. 2023;44(7):425–441. doi:10.1016/j.tips.2023.04.003 google scholar
  49. D’Aloisio V, Dognini P, Hutcheon GA, Coxon CR. PepTherDia database. Drug Discov Today. 2021;26(6):1409–1419. doi:10.1016/j.drudis.2021.02.019 google scholar
  50. Costa L, Sousa E, Fernandes C. Cyclic peptides in pipeline. Pharmaceuticals. 2023;16(7):996. doi:10.3390/ph16070996 google scholar
  51. Menacho-Melgar R, Decker JS, Hennigan JN, Lynch MD. Lipidation in peptide therapeutics. J Control Release. 2019;295:1–12. doi:10.1016/j.jconrel.2018.12.032 google scholar
  52. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309–325. doi:10.1038/s41573-020-00135-8 google scholar
  53. Basith S, Manavalan B, Shin TH, Lee G. Machine intelligence in peptide therapeutics. Med Res Rev. 2020;40(4):1276–1314. doi:10.1002/med.21658 google scholar
  54. D’Annessa I, Di Leva FS, et al. Bioinformatics toolbox for peptide design. Front Mol Biosci. 2020;7. doi:10.3389/fmolb.2020.00066 google scholar
  55. Shaker B, Ahmad S, Lee J, Jung C, Na D. In silico methods and tools for drug discovery. Comput Biol Med. 2021;137:104851. doi:10.1016/j.compbiomed.2021.104851
  56. Cabri W, Cantelmi P, Corbisiero D, et al. Therapeutic peptides targeting PPI. Front Mol Biosci. 2021;8. doi:10.3389/fmolb.2021.697586 google scholar
  57. Nada H, Choi Y, Kim S, et al. Protein–protein interaction modulators. Signal Transduct Target Ther. 2024;9(1). doi:10.1038/s41392-024-02036-3 google scholar
  58. Lee ACL, Harris JL, Khanna KK, Hong JH. Advances in peptide drug development. Int J Mol Sci. 2019;20(10):2383. doi:10.3390/ijms20102383 google scholar
  59. Li CM, Haratipour P, Lingeman RG, et al. Novel peptide therapeutics for cancer. Cells. 2021;10(11):2908. doi:10.3390/cells10112908 google scholar
  60. Guryanov I, Tennikova T, Urtti A. Peptide inhibitors of VEGF-A. Pharmaceutics. 2021;13(9):1337. doi:10.3390/pharmaceutics13091337 google scholar
  61. Wang L, Zhou L, Reille-Seroussi M, et al. Peptidic antagonists of VEGFR1. J Med Chem. 2017;60(15):6598–6606. doi:10.1021/acs.jmedchem.7b00283 google scholar
  62. Karami E, Sabatier JM, Behdani M, et al. Nanobody-derived mimotope against VEGF. J Enzyme Inhib Med Chem. 2020;35(1):1233–1239. doi:10.1080/14756366.2020.1758690 google scholar
  63. Zanella S, Bocchinfuso G, De Zotti M, et al. Antiangiogenic helical oligopeptides. Front Chem. 2019;7. doi:10.3389/fchem.2019.00170 google scholar
  64. Doppalapudi VR, Huang J, Liu D, et al. Chemical generation of bispecific antibodies. PNAS. 2010;107(52):22611–22616. doi:10.1073/pnas.1016478108 google scholar
  65. Chen X, Zhang Z, Wang L, et al. VEGFR-3 imaging peptide radiotracer. Eur J Nucl Med Mol Imaging. 2024;51(8):2338–2352. doi:10.1007/s00259-024-06661-6 google scholar
  66. Coppock MB, Warner CR, Dorsey B, et al. Protein catalyzed capture agents. Biopolymers. 2017;108(2). doi:10.1002/bip.22934 google scholar
  67. Chang YW, Su CM, Su YH, et al. Novel peptides suppress VEGFR-3 activity. Oncotarget. 2014;5. www.impactjournals.com/oncotarget/ google scholar
  68. Zhang Y, He B, Liu K, et al. Novel peptide binding to VEGF receptor. Signal Transduct Target Ther. 2017;2. doi:10.1038/sigtrans.2017.10 google scholar
  69. Balsera B, Bonache MÁ, Reille-Seroussi M, et al. Disrupting VEGF–VEGFR1 interaction. Molecules. 2017;22(11). doi:10.3390/molecules22111846 google scholar
  70. Dmytriyeva O, De Diego Ajenjo A, Lundø K, et al. VEGF-B mimetic peptides. ACS Chem Neurosci. 2020;11(9):1270–1282. doi:10.1021/acschemneuro.9b00685 google scholar
  71. Piossek C, Schneider-Mergener J, et al. VEGFR II-derived peptides inhibit VEGF. J Biol Chem. 1999;274(9):5612–5619. doi:10.1074/jbc.274.9.5612 google scholar
  72. Guryanov I, Korzhikov-Vlakh V, et al. Conformationally constrained VEGF-binding peptides. J Med Chem. 2021;64(15):10900–10907. doi:10.1021/acs.jmedchem.1c00219 google scholar
  73. De Rosa L, Diana D, Basile A, et al. VEGF inhibitor β-hairpin peptide. Eur J Med Chem. 2014;73:210–216. doi:10.1016/j.ejmech.2013.12.016 google scholar
  74. De Rosa L, Capasso D, Diana D, et al. Stabilization of VEGF-mimetic peptide. Eur J Med Chem. 2021;222. doi:10.1016/j.ejmech.2021.113575 google scholar
  75. Caporale A, Martin AD, Capasso D, et al. PlGF-derived peptides binding VEGFRs. J Pept Sci. 2019;25(5). doi:10.1002/psc.3146 google scholar
  76. De Rosa L, Finetti F, Diana D, et al. Miniaturizing VEGF. Sci Rep. 2016;6. doi:10.1038/srep31295 google scholar
  77. Farzaneh Behelgardi M, Zahri S, Mashayekhi F, et al. VEGF-mimicking peptide inhibits angiogenesis. Sci Rep. 2018;8(1). doi:10.1038/s41598-018-36394-0 google scholar